Our internationally-renowned team advises on all types of IP issues in the field of Pharmaceuticals.
Our Pharmaceuticals group enjoys an international reputation, and we are proud to have represented a wide range of companies on contentious and non-contentious matters touching on every stage of the product life-cycle.
Several members of the group have previously held in-house positions within the pharmaceutical industry and we actively leverage this experience across the group. Many of the group are active members of the Pharmaceutical Trade Marks Group (PTMG), and also the Bio Industry Association (BIA) where we have a seat on its Intellectual Property Advisory Committee.
We work regularly alongside in-house legal counsel, and are equally comfortable directly liaising with colleagues in R&D, Business Development, Regulatory and Commercial affairs.
Our attorneys and solicitors have significant experience in advising on all types of IP issues relevant to the pharmaceuticals sector, including patent prosecution, trade mark issues, including the interface with regulatory matters, design protection and enforcement, and contentious work, including oppositions and litigation. We also have expertise in obtaining patent term extensions and providing commercial advice on infringement and validity, licensing opportunities, and parallel imports.
We are active across the Life Sciences field and work with a wide range of technologies from new APIs and manufacturing processes, to formulations, medical uses and diagnostic processes, biotechnological inventions, as well as cosmetics and nutraceuticals.
Some of the technologies we have recently advised on include:
We represent clients from around the world, including Australia, Canada, China, Germany, India, Israel, Japan, New Zealand, Portugal, South Korea, the UK and the US.
Eli Lilly v Genentech – Warner-Lambert Supreme Court Plausibility Test Applied Following the highly anticipated Supreme Court decision in Warner-Lambert v Generics in relation to plausibility at the end of last year, the UK High Court has recently applied the new plausibility test for the first time in Eli Lilly v Genentech Inc.1 Eli Lilly… Read more »
Reporting on the Queen Mary University’s Life Sciences, Cosmetics and Intellectual Property seminars for CNIPA Consulting Patent Attorney Julie Barrett-Major recently gave two 3-hour seminars at the Queen Mary University of London (QMUL) earlier this month on Life Sciences, Cosmetics and Intellectual Property. The two seminars formed part of the QMUL’s programme of education and training… Read more »